Design and synthesis of dual-action inhibitors targeting histone deacetylases and 3-hydroxy-3-methylglutaryl coenzyme a reductase for cancer treatment

Journal of Medicinal Chemistry

Volumn 56, Issue 9, 2013, Pages 3645-3655

  Chen, Jhih Bin ^a   Chern, Ting Rong ^b   Wei, Tzu Tang ^d   Chen, Ching Chow ^d   Lin, Jung Hsin ^a,b,c   Fang, Jim Min ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b RESEARCH CENTER FOR APPLIED SCIENCES   (Taiwan)

^c INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^d School of Medicine   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

7(2(4 FLUOROPHENYL) 5 ISOPROPYL 3 PHENYL 4 PHENYLCARBAMOYLPYRROL 1 YL] 3,5 DIHYDROXY N HYDROXYHEPTANAMIDE; 7(4(4 FLUOROPHENYL) 2 (N METHYL (METHYLSULFONYL) AMINO) 6 ISOPROPYLPYRIMIDIN 5 YL) 3,5 DIHYDROXY N HYDROXYHEPT 6 ENOIC AMIDE; 8[((4(1(7 (HYDROXYAMINO) 7 OXOHEPTYL) 1H 1,2,3 TRIAZOL 4 YLBENZYLCARBAMOYLOXY) 2,6 DIMETHYL 1,2,6,7,8,8A HEXAHYDRONAPHTHYL)ETHYL] 4 [(TERTBUTYLDIMETHYLSILYL)OXY] 3,4,5,6 TETRAHYDRO 2H PYRAN 2 ONE; 8[(4(1(7 (HYDROXYAMINO) 7OXOHEPTYL) 1H 1,2,3 TRIAZOL 4 YL)PHENYLCARBAMOYL)OXY] 2,6 DIMETHYL 1,2,6,7,8,8A HEXAHYDRONAPHTHYLETHYL 4 (TERTBUTYLDIMETHYLSILYLOXY) 3,4,5,6 TETRAHYDRO 2H PYRAN 2 ONE; 8[(7 (HYDROXYAMINO) 7 OXOHEPTYL] CARBAMOYLOXY 2,6 DIMETHYL 1,2,6,7,8,8A HEXAHYDRONAPHTHYLETHYL 4 [(TERT BUTYLDIMETHYLSILYL) OXY] 3,4,5,6 TETRAHYDRO 2H PYRAN 2 ONE; ATORVASTATIN; HEXAHYDRO 2,6 DIMETHYL 8[(2 DIMETHYLBUTYRYLOXY) NAPHTHALENYL] 3,5 DIHYDROXY N HYDROXYHEPTANAMIDE; HEXAHYDRO 2,6 DIMETHYL 8[(2 METHYLBUTYRYLOXY) NAPHTHALENYL] 3,5 DIHYDROXY N HYDROXYHEPTANAMIDE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; ROSUVASTATIN; SIMVASTATIN; UNCLASSIFIED DRUG; VORINOSTAT;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MOLECULAR MODEL; MOUSE; NONHUMAN; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY TECHNIQUES, SYNTHETIC; DRUG DESIGN; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MODELS, MOLECULAR; PROTEIN CONFORMATION;

EID: 84877704473     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm400179b     Document Type: Article

References (36)

1. Kwak, E. L.; Clark, J. W.; Chabner, B. Targeted agents: the rules of combination Clin. Cancer Res. 2007, 13, 5232-5237
2. Sawyers, C. L. Cancer: mixing cocktails Nature 2007, 449, 993-996
3. Zimmermann, G. R.; Lehár, J.; Keith, C. T. Multi-target therapeutics: when the whole is greater than the sum of the parts Drug Discovery Today 2007, 12, 34-42
4. Keith, C. T.; Borisy, A. A.; Stockwell, B. R. Multicomponent therapeutics for networked systems Nat. Rev. Drug Discovery 2005, 4, 71-78
5. Jenuwein, T.; Allis, C. D. Translating the histone code Science 2001, 293, 1074-1080
6. Simone, C.; Peserico, A. Physical and functional HAT/HDAC interplay regulates protein acetylation balance J. Biomed. Biotechnol. 2011, 2011 art. no. 371832
7. Witt, O.; Deubzer, H. E.; Milde, T.; Oehme, I. HDAC family: what are the cancer relevant targets? Cancer Lett. 2009, 277, 8-21
8. Bolden, J. E.; Peart, M. J.; Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors Nat. Rev. Drug Discovery 2006, 5, 769-784
9. Lane, A. A.; Chabner, B. A. Histone deacetylase inhibitors in cancer therapy J. Clin. Oncol. 2009, 27, 5459-5468
10. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy Cancer Lett. 2008, 269, 7-17
11. Hawk, E.; Viner, J. L. Statins and cancer-beyond the "one drug, one disease" model N. Engl. J. Med. 2005, 352, 2238-2239
12. Minder, C. M.; Blaha, M. J.; Horne, A.; Michos, E. D.; Kaul, S.; Blumenthal, R. S. Evidence-based use of statins for primary prevention of cardiovascular disease Am. J. Med. 2012, 125, 440-446
13. Jakobisiak, M.; Golab, J. Statins can modulate effectiveness of antitumor therapeutic modalities Med. Res. Rev. 2010, 30, 102-135
14. Gan, Y.; Wang, J.; Coselli, J.; Wang, X. L. Synergistic induction of apoptosis by HMG-CoA reductase inhibitor and histone deacetylases inhibitor in HeLa cells Biochem. Biophys. Res. Commun. 2008, 365, 386-392
15. Lin, Y.-C.; Lin, J.-H.; Chou, C.-W.; Chang, Y.-F.; Yeh, S.-H.; Chen, C.-C. Statins increase p21 through inhibition of histone deacetylase activity and release of promoter-associated HDAC1/2 Cancer Res. 2008, 68, 2375-2383
16. Morphy, R.; Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm J. Med. Chem. 2005, 48, 6523-6543
17. Frantz, S. The trouble with making combination drugs Nat. Rev. Drug Discovery 2006, 5, 881-882
18. Medina-Franco, J. L.; Giulianotti, M. A.; Welmaker, G. S.; Houghten, R. A. Shifting from the single to the multitarget paradigm in drug discovery. Drug Discovery Today [Online early access]. DOI: 10.1016/ j.drudis.2013.01.008. Published Online: Jan 20, 2013. http://dx.doi.org/10.1016/j.drudis.2013.01.008.
19. Chen, L.; Wilson, D.; Jayaram, H. N.; Pankiewicz, K. W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment J. Med. Chem. 2007, 50, 6685-6691
20. Chen, L.; Petrelli, R.; Gao, G.; Wilson, D. J.; McLean, G. T.; Jayaram, H. N.; Sham, Y. Y.; Pankiewicz, K. W. Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylase based on a cinnamic hydroxamic acid core structure Bioorg. Med. Chem. 2010, 18, 5950-5964
21. Tavera-Mendoza, L. E.; Quach, T. D.; Dabbas, B.; Hudon, J.; Liao, X.; Palijan, A.; Gleason, J. L.; White, J. H. Incorporation of histone deacetylase inhibition into the structure of a nuclear receptor agonist Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 8250-8255
22. Mahboobi, S.; Dove, S.; Sellmer, A.; Winkler, M.; Eichhorn, E.; Pongratz, H.; Ciossek, T.; Baer, T.; Maier, T.; Beckers, T. Design of chimeric histone deacetylase-and tyrosine kinase-inhibitors: a series of imatinib hybrides as potent inhibitors of wild-type and mutant BCR-ABL, PDGF-Rβ, and histone deacetylases J. Med. Chem. 2009, 52, 2265-2279
23. Cai, X.; Zhai, H.-X.; Wang, J.; Forrester, J.; Qu, H.; Yin, L.; Lai, C.-J.; Bao, R.; Qian, C. Discovery of 7-(4-(3-ethynylphenylamino)-7- methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDc-101) as a potent multi-acting HDAC, EGFR, and HER2 inhibitor for the treatment of cancer J. Med. Chem. 2010, 53, 2000-2009
24. Guerrant, W.; Patil, V.; Canzoneri, J. C.; Oyelere, A. K. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors J. Med. Chem. 2012, 55, 1465-1477
25. O'Boyle, N. M.; Meegan, M. J. Designed multiple ligands for cancer therapy Curr. Med. Chem. 2011, 18, 4722-4737
26. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands Drug Discovery Today 2004, 9, 641-651
27. Chen, P. C.; Patil, V.; Guerrant, W.; Green, P.; Oyelere, A. K. Synthesis and structure-activity relationship of histone deacetylase (HDAC) inhibitors with triazole-linked cap group Bioorg. Med. Chem. 2008, 16, 4839-4853
28. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401, 188-193
29. Istvan, E. S.; Deisenhofer, J. Structural mechanism for statin inhibition of HMG-CoA reductase Science 2001, 292, 1160-1164
30. Orchid Research Laboratories Ltd. Novel hydroxamates. Indian Patent Appl. 1492/CHE/2007, 2007.
31. Dompierre, J. P.; Godin, J. D.; Charrin, B. C.; Cordelieres, F. P.; King, S. J.; Humbert, S.; Saudou, F. Histone deacetylase 6 inhibition compensates for the transport deficit in Huntington's disease by increasing tubulin acetylation J. Neurosci. 2007, 27, 3571-3583
32. Bressi, J. C.; Jennings, A. J.; Skene, R.; Wu, Y.; Melkus, R.; De Jong, R.; O'Connell, S.; Grimshaw, C. E.; Navre, M.; Gangloff, A. R. Exploration of the HDAC2 foot pocket: ynthesis and SAR of substituted N-(2-aminophenyl) benzamides Bioorg. Med. Chem. Lett. 2010, 20, 3142-3145
33. Morris, G. M.; Huey, R.; Lindstrom, W.; Sanner, M. F.; Belew, R. K.; Goodsell, D. S.; Olson, A. J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility J. Comput. Chem. 2009, 30, 2785-2791
34. O'Boyle, N. M.; Banck, M.; James, C. A.; Morley, C.; Vandermeersch, T.; Hutchison, G. R. Open Babel: an open chemical toolbox. J. Cheminf. 2011, 3, No. 33.
35. Wang, J.-C.; Lin, J.-H.; Chen, C.-M.; Perryman, A. L.; Olson, A. J. Robust scoring functions for protein-ligand interactions with quantum chemical charge models J. Chem. Inf. Model. 2011, 51, 2528-2537
36. Wang, J.-C.; Chu, P.-Y.; Chen, C.-M.; Lin, J.-H. idTarget: a Web server for identifying protein targets of small chemical molecules with robust scoring functions and a divide-and-conquer docking approach Nucleic Acids Res. 2012, 40, W393-W399